Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 14Recruiting 6Withdrawn 4Terminated 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Myeloid 1Lymphoid 1Genitourinary 1Classical hematology 1

Conditions

Multiple Myeloma 2Thrombocytosis 1Thrombocytopenia 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Follicular 1Kidney Neoplasms 1Cytokine Release Syndrome 1Carcinoma, Renal Cell 1Anemia 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Interventional × siltuximab × Clear all
NCT06352866 2025-03-03

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Case Comprehensive Cancer Center

Phase 2 Withdrawn
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT02805868 2016-10-24

Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Northwestern University

Phase EARLY_PHASE1 Withdrawn
Classical hematologyLymphoidMyeloid

Anemia, Lymphoma, Follicular, Polycythemia Vera, Thrombocytopenia, Thrombocytosis, Primary Myelofibrosis

NCT00311545 2013-02-20

S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer

SWOG Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01266811 2013-01-28

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Centocor, Inc.

Phase 3 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡